HER-2/neu detection in fine-needle aspirates of breast cancer: Fluorescence in situ hybridization and immunocytochemical analysis

American Journal of Clinical Pathology

Volumn 122, Issue 2, 2004, Pages 246-255

  Beatty, Barbara G ^a   Bryant, Ronald ^a   Wang, Weichen ^a   Ashikaga, Takamaru ^a   Gibson, Pamela C ^a   Leiman, Gladwyn ^a   Weaver, Donald L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Fine needle aspirate; Fluorescence in situ hybridization; HER 2 neu; Immunocytochemistry; Immunohistochemistry

Indexed keywords

ALCOHOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY;

EID: 3242748117     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/X8UP920UF4XM1C5C     Document Type: Article

References (42)

1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165-184.
2. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125-138.
3. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1997;34:791-808.
4. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
5. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
6. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79:1220-1226.
7. Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997;3:593-600.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
9. Gullick W, Love S, Wright C, et al. c-erb B-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434-438.
10. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer. 1994;74:2956-2963.
11. Rilke F, Colnaghi M, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;39:44-49.
12. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567.
13. Press MF, Pike M, Chazin V, et al. HER-2/neu expression in node-negative breast cancers: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.
14. Vogel C, Cobleigh M, Tripathy D, et al. Efficacy and safety of trastuzumab (Herceptin) as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
15. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-H (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu in human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
16. Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
17. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5:199-207.
18. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
19. Hoang MP, Sahin AA, Ordonez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852-859.
20. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol. 2002;13:1398-1403.
21. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer. 1999;80:519-525.
22. McManus DT, Patterson AH, Maxwell P, et al. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol. 1999;52:75-77.
23. Klijanienko J, Couturier J, Galut M, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer. 1999;87:312-318.
24. Sauter G, Feichter G, Torhorst J, et al. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol. 1996;40:164-173.
25. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1973.
26. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
27. Slamon DJ, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
28. Mass RD, Press MF, Anderson S, et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract]. Proc Oncol. 2001;20:22a. Abstract 85.
29. Press M, Bernstein L, Thomas P. HER-2/neu gene amplification by fluorescence in situ hybridization: evaluation of archival specimens and utility as a marker of poor prognosis in node negative invasive breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
30. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
31. Couturier J, Vincent-Saloman A, Nicolas A, et al. Strong correlation between results in fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000;13:1238-1243.
32. Klorin G, Keren R. Prognostic markers in histologic and cytologic specimens of breast cancer. Anal Quant Cytol Histol. 2003;5:297-302.
33. Troncone G, Panico L, Vetrani A, et al. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol. 1996;14:135-139.
34. Jorda M, Ganjei P, Nadji M. Retrospective c-erbB-2 immunostaining in aspiration cytology of breast cancer. Diagn Cytopathol. 1993;11:262-265.
35. Corkill ME, Katz R. Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol. 1993;11:250-254.
36. Nizzoli R, Bozzetti C, Crafa P, et al. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol. 2003;28:142-146.
37. DiGiovanna MP, Chu P, Davison TL, et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 2002;62:6667-6673.
38. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HRE-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
39. Masood S, Bui MM. Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci. 2000;30:259-265.
40. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001;61:5345-5348.
41. Shimizu C, Fukutomi T, Tsuda H, et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol. 2000;73:17-20.
42. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.